Q-omics provides the consensus-scored LIN7A profile across patient tissues and cancer cell-line models. LIN7A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LIN7A is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, LIN7A protein abundance shows 20,874 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KIRC, LUAD, and UCEC as cancer lineages where LIN7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIN7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIN7A survival associations across molecular data types. LIN7A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIN7A RNA expression–survival associations across cancer types. High LIN7A expression shows unfavorable associations in STAD, BLCA, ACC and UVM, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LIN7A RNA expression.
This table summarizes LIN7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LIN7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIN7A shows lower tumor expression in LUAD, THCA, LUSC and BRCA and higher tumor expression in HNSC and KICH. The LUAD box plot shows higher LIN7A RNA expression in normal versus tumor tissue (log2 FC = −2.806, t-test p < 0.001).
This table shows molecular features associated with LIN7A in patient tissues and cancer cell lines. In patient samples, LIN7A shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, LIN7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
